treated with Atacicept developed profound reductions in their serum IgG levels. Patient 3 dropped their IgG level to 2.9 g/l and developed pneumonia due to haemophilus infl uenzae. Patient 13 had an IgG level down to 2.5 g/l and developed pneumonia due to Legionella pneumophila; and Patient 14 also dropped her IgG level to 2.5 g/l, subsequently developing Bacillus bacteraemia.
Although to quote Paul Simon there had been 'hints and allegations' that high-dose corticosteroids can reduce IgG synthesis [2] , neither the authors of the Ginzler study nor any colleagues I have spoken to in rheumatology or nephrology could recall seeing anything like these very profound falls in IgG levels within a fortnight of starting steroids and mycophenolate. In reality, I suspect, few clinicians actually measure immunoglobulin levels in these circumstances. In addition, as Ginzler and colleagues point out, hypogammaglobulinemia has been reported in approximately one-half of renal transplant patients receiving mycophenolate and a combination of corticosteroids [3] -but again this has not, to the best of my knowledge, been reported in patients with lupus nephritis, who are these days often treated in this way. Indeed, the recent success of the Aspriva Lupus Management Study trials suggest that this combination may be used even more widely in the future [4, 5] .
Another warning sign of impending trouble was the very low CD4 counts identifi ed in those patients who went on to develop pneumonia. Th ese CD4 levels should also be monitored.
Fortunately, there were no fatalities in this study, but two questions do emerge and are not, I think, easily answered. First, was the company simply unlucky with their choice of patients? Th e patients who were eventually randomised to Atacicept had high levels of proteinuria at screening, implying that they had particularly aggressive disease. Th ese patients are likely to have received more immunosuppression previously. Patients with signifi cant proteinuria are also likely to be leaking IgG in the urine. Th ey therefore need higher IgG production to maintain normal serum levels, and may be sensitive to drugs that interfere with this production. In future, it is reasonable to anticipate that pharmacogenomics may provide an essential guide to which drugs will better suit which individual patients. Two of the patients whose immunoglobulin levels dropped so rapidly were African-Americans and one was Asian. It might perhaps be relevant that diff erences emerged in the responses to mycophenolate and cyclophosphamide in the original Aspriva Lupus Management Study depending on ethnicity [6] . More Black and Hispanic patients therefore responded to mycophenolate than to cyclophosphamide.
Secondly, should the company have continued the study, since we are no closer to knowing whether or not Atacicept might of value in treating patients with lupus nephritis -especially those who do not respond to conventional immunosuppression? Meryl Streep has of course gone on to star in another leading role as Th e Iron Lady -alias Margaret Th atcher. Would the company been better served by an Iron Lady (or possibly an Iron Man!) who would have pointed out that the dramatic falls in IgG commenced prior to the introduction of Atacicept (although, admittedly, some continuing fall did take place in two of these patients after the Atacicept was started)that is, the biologic was not the initial culprit. Such an Iron Lady might have persuaded the Safety Committee that, provided the IgG level on day 1 of the trial (before Atacicept was given) was well within normal limits, there really would be no reason to stop the study, which was important and must, of course, have cost many millions of dollars to get started.
Th ese events occurred over 3 years ago. Even allowing for the inevitable delays to review the data carefully, it seems regrettable that a novel message -that is, the importance of measuring immunoglobulin (and possibly CD4) levels after starting patients on mycophenolate and high-dose steroids prior to the introduction of Atacicepthas taken so long to be published. One wonders what Meryl Streep (in the guise of Mrs Th atcher) would have thought about this. I suspect she would not have been amused.
